Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-6584
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study ; day:10 ; month:1 ; year:2019 ; pages:1-15
Rheumatology and therapy ; (10.1.2019), 1-15
- Creator
-
Darloy, Jean
Segaud, Nicolas
Salmon, Jean-Hugues
Eschard, Jean-Paul
Goëb, Vincent
Deprez, Xavier
Guyot, Marie-Hélène
Houvenagel, Eric
Lecuyer, Nicolas
Marguerie, Laurent
Gally, Samuel
Pau, David
Idier, Isabelle
Baudens, Guy
Flipo, René-Marc
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40744-018-0138-y
- URN
-
urn:nbn:de:101:1-2019021623012132713343
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Darloy, Jean
- Segaud, Nicolas
- Salmon, Jean-Hugues
- Eschard, Jean-Paul
- Goëb, Vincent
- Deprez, Xavier
- Guyot, Marie-Hélène
- Houvenagel, Eric
- Lecuyer, Nicolas
- Marguerie, Laurent
- Gally, Samuel
- Pau, David
- Idier, Isabelle
- Baudens, Guy
- Flipo, René-Marc
- SpringerLink (Online service)
Other Objects (12)
Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis
Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: effect on quality of life after liver transplantation
MEMS optical switch: Switching time reduction
Health-related quality of life in patients with common variable immunodeficiency switching from intravenous to subcutaneous immunoglobulin therapy
Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
Practice of switch from intravenous to oral antibiotics
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report
Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis
Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: effect on quality of life after liver transplantation
MEMS optical switch: Switching time reduction
Health-related quality of life in patients with common variable immunodeficiency switching from intravenous to subcutaneous immunoglobulin therapy
Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
Practice of switch from intravenous to oral antibiotics
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report
Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis
Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: effect on quality of life after liver transplantation
MEMS optical switch: Switching time reduction
Health-related quality of life in patients with common variable immunodeficiency switching from intravenous to subcutaneous immunoglobulin therapy
Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
Practice of switch from intravenous to oral antibiotics
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis